| Code | CSB-RA004783MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to carlumab, targeting CCL2 (C-C motif chemokine ligand 2), also known as monocyte chemoattractant protein-1 (MCP-1). CCL2 is a critical chemokine that mediates the recruitment of monocytes, macrophages, and other immune cells to sites of inflammation through binding to its receptor CCR2. This chemokine plays a pivotal role in inflammatory responses and has been implicated in various pathological conditions, including cancer progression, metastasis, atherosclerosis, rheumatoid arthritis, and fibrotic diseases. Elevated CCL2 levels in the tumor microenvironment are associated with immune suppression and poor prognosis in multiple malignancies.
Carlumab is a fully humanized IgG1κ monoclonal antibody that was developed to neutralize CCL2 activity and was evaluated in clinical trials for cancer therapy. This biosimilar antibody serves as a valuable research tool for investigating CCL2-mediated signaling pathways, studying chemokine biology, examining inflammatory mechanisms, and exploring therapeutic interventions in preclinical disease models where CCL2 contributes to pathogenesis.
There are currently no reviews for this product.